Clinical trial · no report yet · Phase 1/Phase 2
TREC
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
- NCT01165112 ↗
- Completed
- University of Washington
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II Trial of Bendamustine/Treanda®, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma
- Interventions
- Bendamustine Hydrochloride; Carboplatin; Rituximab; Etoposide; Laboratory Biomarker Analysis
- Arms
- Treatment (chemotherapy and monoclonal antibody therapy) · Experimental
- Enrollment
- 48
- Primary outcomes
- Maximally Tolerated Dose of Bendamustine Hydrochloride That Can be Combined With Rituximab, Carboplatin, and Etoposide Chemotherapy in Patients With Relapsed or Refractory Lymphoid Malignancies
- Safety and Toxicity of This Regimen
- Sponsor
- University of Washington with National Cancer Institute (NCI)
- Start
- Sep 2010
- Primary completion
- Jun 2015
- Results posted
- Yes
- Registry record
- NCT01165112 · updated Dec 5, 2018
Publications
linked from the registry- Budde LE, Wu D, Martin DB, Philip M, Shustov AR, Smith SD, Gooley TA, Chen TL, Libby EN, Chen EY, Kojouri K, Langerak A, Roden JE, Press OW, Gopal AK. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14. PubMed 30596402